Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 1/2013

01-01-2013 | Review

The role of innate immunity in HBV infection

Authors: Qiuju Han, Cai Zhang, Jian Zhang, Zhigang Tian

Published in: Seminars in Immunopathology | Issue 1/2013

Login to get access

Abstract

Hepatitis B virus (HBV) infection is one of the main causes of chronic liver diseases. Whether HBV infection is cleared or persists is determined by both viral factors and host immune responses. It becomes clear that innate immunity is of importance in protecting the host from HBV infection and persistence. However, HBV develops strategies to suppress the antiviral immune responses. A combined therapeutic strategy with both viral suppression and enhancement of antiviral immune responses is needed for effective long-term clearance and cure for chronic HBV infection. We and others confirmed that bifunctional siRNAs with both gene silencing and innate immune activation properties are beneficial for inhibition of HBV and represent a potential approach for treatment of viral infection. Understanding the nature of liver innate immunity and their roles in chronic HBV progression and HBV clearance may aid in the design of novel therapeutic strategies for chronic HBV infection.
Literature
1.
Das A, Maini MK (2010) Innate and adaptive immune responses in hepatitis B virus infection. Dig Dis 28(1):126–132PubMedCrossRef
2.
Zhai Y, Busuttil RW, Kupiec-Weglinski JW (2011) Liver ischemia and reperfusion injury: new insights into mechanisms of innate-adaptive immune-mediated tissue inflammation. Am J Transplant 11(8):1563–1569PubMedCrossRef
3.
4.
5.
Guo H, Jiang D, Ma D, Chang J, Dougherty AM, Cuconati A, Block TM, Guo JT (2009) Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol 83(2):847–858PubMedCrossRef
6.
Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5(7):730–737PubMedCrossRef
7.
Abreu MT (2010) Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 10(2):131–144PubMedCrossRef
8.
Bertoletti A, Ferrari C (2003) Kinetics of the immune response during HBV and HCV infection. Hepatology 38(1):4–13PubMedCrossRef
9.
Kadowaki N, Antonenko S, Lau JY, Liu YJ (2000) Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 192(2):219–226PubMedCrossRef
10.
Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A, Dunn C, Pallant C, Ellis G, Khanna P, Dusheiko G, Gilson RJ, Maini MK (2010) Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog 6(12):e1001227PubMedCrossRef
11.
Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z (2010) Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 91(Pt 8):2080–2090PubMedCrossRef
12.
Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV (1996) Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4(1):25–36PubMedCrossRef
13.
Jirillo E, Caccavo D, Magrone T, Piccigallo E, Amati L, Lembo A, Kalis C, Gumenscheimer M (2002) The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res 8(5):319–327PubMed
14.
Seki S, Habu Y, Kawamura T, Takeda K, Dobashi H, Ohkawa T, Hiraide H (2000) The liver as a crucial organ in the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+T cells in T helper 1 immune responses. Immunol Rev 174:35–46PubMedCrossRef
15.
Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, Krux F, Dittmer U, Roggendorf M, Gerken G, Schlaak JF (2007) Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 46(6):1769–1778PubMedCrossRef
16.
Chen Y, Sun R, Jiang W, Wei H, Tian Z (2007) Liver-specific HBsAg transgenic mice are over-sensitive to Poly(I:C)-induced liver injury in NK cell- and IFN-gamma-dependent manner. J Hepatol 4(2):183–190CrossRef
17.
Dong Z, Wei H, Sun R, Hu Z, Gao B, Tian Z (2004) Involvement of natural killer cells in PolyI:C-induced liver injury. J Hepatol 41(6):966–973PubMedCrossRef
18.
Wieland S, Thimme R, Purcell RH, Chisari FV (2004) Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 101(17):6669–6674PubMedCrossRef
19.
Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar RM, Brown D, Gilson RJ, Tedder RJ, Dusheiko GM, Jacobs M, Klenerman P, Maini MK (2009) Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137(4):1289–1300PubMedCrossRef
20.
Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17:189–220PubMedCrossRef
21.
Lanier LL (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9(5):495–502PubMedCrossRef
22.
Chen M, Sallberg M, Hughes J, Jones J, Guidotti LG, Chisari FV, Billaud JN, Milich DR (2005) Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 79(5):3016–3027PubMedCrossRef
23.
Bonorino P, Ramzan M, Camous X, Dufeu-Duchesne T, Thelu MA, Sturm N, Dariz A, Guillermet C, Pernollet M, Zarski JP, Marche PN, Leroy V, Jouvin-Marche E (2009) Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol 51(3):458–467PubMedCrossRef
24.
Nattermann J, Feldmann G, Ahlenstiel G, Langhans B, Sauerbruch T, Spengler U (2006) Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 55(6):869–877PubMedCrossRef
25.
Tjwa ET, van Oord GW, Hegmans JP, Janssen HL, Woltman AM (2011) Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol 54(2):209–218PubMedCrossRef
26.
Zhang Z, Zhang S, Zou Z, Shi J, Zhao J, Fan R, Qin E, Li B, Li Z, Xu X, Fu J, Zhang J, Gao B, Tian Z, Wang FS (2011) Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 53:73–85PubMedCrossRef
27.
Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, Mavilio D, De Filippi F, Bruno S, Mondelli MU (2009) Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 137(3):1151–1160, 1160 e1151-1157PubMedCrossRef
28.
Tang KF, Chen M, Xie J, Song GB, Shi YS, Liu Q, Mei ZC, Steinle A, Ren H (2009) Inhibition of hepatitis B virus replication by small interference RNA induces expression of MICA in HepG2.2.15 cells. Med Microbiol Immunol 198(1):27–32PubMedCrossRef
29.
Ju Y, Hou N, Meng J, Wang X, Zhang X, Zhao D, Liu Y, Zhu F, Zhang L, Sun W, Liang X, Gao L, Ma C (2010) T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol 52(3):322–329PubMedCrossRef
30.
Tripp CS, Wolf SF, Unanue ER (1993) Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 90(8):3725–3729PubMedCrossRef
31.
Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HL (2011) Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS One 6(1):e15324PubMedCrossRef
32.
Della Chiesa M, Romagnani C, Thiel A, Moretta L, Moretta A (2006) Multidirectional interactions are bridging human NK cells with plasmacytoid and monocyte-derived dendritic cells during innate immune responses. Blood 108(12):3851–3858PubMedCrossRef
33.
Gao B, Radaeva S, Park O (2009) Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol 86(3):513–528PubMed
34.
Wang FS, Zhang Z (2009) Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus. Expert Rev Gastroenterol Hepatol 3(5):499–512PubMedCrossRef
35.
Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D (2002) Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 16(4):583–594PubMedCrossRef
36.
Li J, Han YP, Liu B, Liu Y, Chen N, Dong L, Yan YD, Jiang LF, Huang ZH (2011) Dynamic changes and clinical significance of HBcAg18-27 specific cytotoxic T lymphocytes in acute hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 19(1):38–43PubMed
37.
van der Molen RG, Sprengers D, Binda RS, de Jong EC, Niesters HG, Kusters JG, Kwekkeboom J, Janssen HL (2004) Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 40(3):738–746PubMedCrossRef
38.
Hasebe A, Akbar SM, Furukawa S, Horiike N, Onji M (2005) Impaired functional capacities of liver dendritic cells from murine hepatitis B virus (HBV) carriers: relevance to low HBV-specific immune responses. Clin Exp Immunol 139(1):35–42PubMedCrossRef
39.
Duan XZ, Wang M, Li HW, Zhuang H, Xu D, Wang FS (2004) Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J Clin Immunol 24(6):637–646PubMedCrossRef
40.
Duan XZ, Zhuang H, Wang M, Li HW, Liu JC, Wang FS (2005) Decreased numbers and impaired function of circulating dendritic cell subsets in patients with chronic hepatitis B infection (R2). J Gastroenterol Hepatol 20(2):234–242PubMedCrossRef
41.
Zhang Z, Chen D, Yao J, Zhang H, Jin L, Shi M, Wang FS (2007) Increased infiltration of intrahepatic DC subsets closely correlate with viral control and liver injury in immune active pediatric patients with chronic hepatitis B. Clin Immunol 122(2):173–180PubMedCrossRef
42.
Woltman AM, Boonstra A, Janssen HL (2010) Dendritic cells in chronic viral hepatitis B and C: victims or guardian angels? Gut 59(1):115–125PubMedCrossRef
43.
Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR, Borrow P, Williams K, Humphreys E, Afford S, Adams DH, Bertoletti A, Maini MK (2007) Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 204(3):667–680PubMedCrossRef
44.
Wang K, Fan X, Fan Y, Wang B, Han L, Hou Y (2007) Study on the function of circulating plasmacytoid dendritic cells in the immunoactive phase of patients with chronic genotype B and C HBV infection. J Viral Hepat 14(4):276–282PubMedCrossRef
45.
Xu Y, Hu Y, Shi B, Zhang X, Wang J, Zhang Z, Shen F, Zhang Q, Sun S, Yuan Z (2009) HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol 46(13):2640–2646PubMedCrossRef
46.
Untergasser A, Zedler U, Langenkamp A, Hosel M, Quasdorff M, Esser K, Dienes HP, Tappertzhofen B, Kolanus W, Protzer U (2006) Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 43(3):539–547PubMedCrossRef
47.
Beckebaum S, Cicinnati VR, Zhang X, Ferencik S, Frilling A, Grosse-Wilde H, Broelsch CE, Gerken G (2003) Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape. Immunology 109(4):487–495PubMedCrossRef
48.
Op den Brouw ML, Binda RS, van Roosmalen MH, Protzer U, Janssen HL, van der Molen RG, Woltman AM (2009) Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 126(2):280–289PubMedCrossRef
49.
van der Molen RG, Sprengers D, Biesta PJ, Kusters JG, Janssen HL (2006) Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology 44(4):907–914PubMedCrossRef
50.
Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, Rodgers S, Kurtovic J, Chang J, Lewin S, Desmond P, Locarnini S (2007) Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 45(1):102–110PubMedCrossRef
51.
Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Bucchi A, Sowa JP, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak JF (2009) Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49(4):1132–1140PubMedCrossRef
52.
Taniguchi T, Takaoka A (2002) The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 14(1):111–116PubMedCrossRef
53.
Wang X, Li Y, Mao A, Li C, Tien P (2010) Hepatitis B virus X protein suppresses virus-triggered IRF3 activation and IFN-beta induction by disrupting the VISA-associated complex. Cell Mol Immunol 7(5):341–348PubMedCrossRef
54.
Han Q, Zhang C, Zhang J, Tian Z (2011) Reverse of HBV-induced immune tolerance by an immunostimulatory 3p-HBx-siRNA in a retinoic acid inducible gene I (RIG-I) -dependent manner. Hepatology 54:1179–1189PubMedCrossRef
55.
Jiang J, Tang H (2010) Mechanism of inhibiting type I interferon induction by hepatitis B virus X protein. Protein Cell 1(12):1106–1117PubMedCrossRef
56.
Fernandez M, Quiroga JA, Carreno V (2003) Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins. J Gen Virol 84(Pt 8):2073–2082PubMedCrossRef
57.
Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M, Chisari FV (2010) Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci USA 107(2):798–802PubMedCrossRef
58.
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9(5):503–510PubMedCrossRef
59.
Tripathy AS, Das R, Chadha MS, Arankalle VA (2011) Epidemic of hepatitis B with high mortality in India: association of fulminant disease with lack of CCL4 and natural killer T cells. J Viral Hepat 18(10):e415–e422PubMedCrossRef
60.
Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, Orlandini A, Sacchelli L, Missale G, Ferrari C (2009) Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58(7):974–982PubMedCrossRef
61.
Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, Brown D, Amlot PL, Williams R, Vergani D, Dusheiko GM, Bertoletti A (2000) Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32(5):1117–1124PubMedCrossRef
62.
Kakimi K, Lane TE, Wieland S, Asensio VC, Campbell IL, Chisari FV, Guidotti LG (2001) Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 194(12):1755–1766PubMedCrossRef
63.
Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV (2002) Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol 169(9):5188–5195PubMed
64.
Scott-Algara D, Mancini-Bourgine M, Fontaine H, Pol S, Michel ML (2010) Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination. PLoS One 5(1):e8761PubMedCrossRef
65.
Kakimi K, Guidotti LG, Koezuka Y, Chisari FV (2000) Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 192(7):921–930PubMedCrossRef
66.
Emoto M, Kaufmann SH (2003) Liver NKT cells: an account of heterogeneity. Trends Immunol 24(7):364–369PubMedCrossRef
67.
Colonna M, Trinchieri G, Liu YJ (2004) Plasmacytoid dendritic cells in immunity. Nat Immunol 5(12):1219–1226PubMedCrossRef
68.
Isogawa M, Robek MD, Furuichi Y, Chisari FV (2005) Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 79(11):7269–7272PubMedCrossRef
69.
Uprichard SL, Wieland SF, Althage A, Chisari FV (2003) Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc Natl Acad Sci USA 100(3):1310–1315PubMedCrossRef
70.
Thompson AJ, Colledge D, Rodgers S, Wilson R, Revill P, Desmond P, Mansell A, Visvanathan K, Locarnini S (2009) Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther 14(6):797–808PubMedCrossRef
71.
Ebert G, Poeck H, Lucifora J, Baschuk N, Esser K, Esposito I, Hartmann G, Protzer U (2011) 5′ Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. Gastroenterology 141(2):696–706, 706 e691-693PubMedCrossRef
72.
Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV (2005) Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci USA 102(28):9913–9917PubMedCrossRef
73.
McClary H, Koch R, Chisari FV, Guidotti LG (2000) Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 74(5):2255–2264PubMedCrossRef
74.
Wieland SF, Guidotti LG, Chisari FV (2000) Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 74(9):4165–4173PubMedCrossRef
75.
Wieland SF, Vega RG, Muller R, Evans CF, Hilbush B, Guidotti LG, Sutcliffe JG, Schultz PG, Chisari FV (2003) Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol 77(2):1227–1236PubMedCrossRef
76.
Bertoletti A, Gehring AJ (2006) The immune response during hepatitis B virus infection. J Gen Virol 87(Pt 6):1439–1449PubMedCrossRef
77.
Allen IC, Scull MA, Moore CB, Holl EK, McElvania-TeKippe E, Taxman DJ, Guthrie EH, Pickles RJ, Ting JP (2009) The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 30(4):556–565PubMedCrossRef
78.
Thomas PG, Dash P, Aldridge JR Jr, Ellebedy AH, Reynolds C, Funk AJ, Martin WJ, Lamkanfi M, Webby RJ, Boyd KL, Doherty PC, Kanneganti TD (2009) The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30(4):566–575PubMedCrossRef
79.
Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A (2009) Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med 206(1):79–87PubMedCrossRef
80.
Schmitz N, Kurrer M, Bachmann MF, Kopf M (2005) Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol 79(10):6441–6448PubMedCrossRef
81.
Sergerie Y, Rivest S, Boivin G (2007) Tumor necrosis factor-alpha and interleukin-1 beta play a critical role in the resistance against lethal herpes simplex virus encephalitis. J Infect Dis 196(6):853–860PubMedCrossRef
82.
Skeldon A, Saleh M (2011) The inflammasomes: molecular effectors of host resistance against bacterial, viral, parasitic, and fungal infections. Front Microbiol 2:15PubMed
83.
Kanneganti TD (2010) Central roles of NLRs and inflammasomes in viral infection. Nat Rev Immunol 10(10):688–698PubMedCrossRef
84.
Lee MO, Choi YH, Shin EC, Kang HJ, Kim YM, Jeong SY, Seong JK, Yu DY, Cho H, Park JH, Kim SJ (2002) Hepatitis B virus X protein induced expression of interleukin 18 (IL-18): a potential mechanism for liver injury caused by hepatitis B virus (HBV) infection. J Hepatol 37(3):380–386PubMedCrossRef
85.
Manigold T, Bocker U, Chen J, Gundt J, Traber P, Singer MV, Rossol S (2003) Hepatitis B core antigen is a potent inductor of interleukin-18 in peripheral blood mononuclear cells of healthy controls and patients with hepatitis B infection. J Med Virol 71(1):31–40PubMedCrossRef
86.
Poeck H, Bscheider M, Gross O, Finger K, Roth S, Rebsamen M, Hannesschlager N, Schlee M, Rothenfusser S, Barchet W, Kato H, Akira S, Inoue S, Endres S, Peschel C, Hartmann G, Hornung V, Ruland J (2010) Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol 11(1):63–69PubMedCrossRef
87.
Rintahaka J, Wiik D, Kovanen PE, Alenius H, Matikainen S (2008) Cytosolic antiviral RNA recognition pathway activates caspases 1 and 3. J Immunol 180(3):1749–1757PubMed
88.
Poeck H, Ruland J (2012) From virus to inflammation: mechanisms of RIG-I-induced IL-1beta production. Eur J Cell Biol 91(1):59–64PubMedCrossRef
89.
Burdette D, Haskett A, Presser L, McRae S, Iqbal J, Waris G (2012) Hepatitis C virus activates interleukin-1{beta} via caspase-1-inflammasome complex. J Gen Virol 93:235–246PubMedCrossRef
90.
Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV (2002) Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 76(21):10702–10707PubMedCrossRef
91.
Lech M, Avila-Ferrufino A, Skuginna V, Susanti HE, Anders HJ (2010) Quantitative expression of RIG-like helicase, NOD-like receptor and inflammasome-related mRNAs in humans and mice. Int Immunol 22(9):717–728PubMedCrossRef
92.
Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G (2011) Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54(1):133–144PubMedCrossRef
93.
Zhu P, Duan L, Chen J, Xiong A, Xu Q, Zhang H, Zheng F, Tan Z, Gong F, Fang M (2011) Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice. Hum Gene Ther 22(7):853–864. doi:10.​1089/​hum.​2010.​145 PubMedCrossRef
94.
Wang J, Sun R, Wei H, Dong Z, Tian Z (2006) Pre-activation of T lymphocytes by low dose of concanavalin A aggravates toll-like receptor-3 ligand-induced NK cell-mediated liver injury. Int Immunopharmacol 6(5):800–807PubMedCrossRef
95.
Chen Y, Wei H, Sun R, Tian Z (2005) Impaired function of hepatic natural killer cells from murine chronic HBsAg carriers. Int Immunopharmacol 5(13–14):1839–1852PubMedCrossRef
96.
Chen Y, Wei H, Sun R, Dong Z, Zhang J, Tian Z (2007) Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells. Hepatology 46(3):706–715PubMedCrossRef
97.
Hou X, Zhou R, Wei H, Sun R, Tian Z (2009) NKG2D-retinoic acid early inducible-1 recognition between natural killer cells and Kupffer cells in a novel murine natural killer cell-dependent fulminant hepatitis. Hepatology 49(3):940–949PubMedCrossRef
98.
Zou Y, Chen T, Han M, Wang H, Yan W, Song G, Wu Z, Wang X, Zhu C, Luo X, Ning Q (2010) Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. J Immunol 184(1):466–475PubMedCrossRef
99.
Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z, Jia Y, Yuan Y, Guan K, Xu Y, Cheng X, Zhang Y, Wang Y, Wen C, Wu Q, Shi W, Zhong H (2010) The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol 185(2):1158–1168PubMedCrossRef
100.
Tay CH, Welsh RM (1997) Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol 71(1):267–275PubMed
101.
Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, Runkel L (1995) Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182(5):1223–1230PubMedCrossRef
102.
Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3(6):673–682PubMedCrossRef
103.
Balkow S, Kersten A, Tran TT, Stehle T, Grosse P, Museteanu C, Utermohlen O, Pircher H, von Weizsacker F, Wallich R, Mullbacher A, Simon MM (2001) Concerted action of the FasL/Fas and perforin/granzyme A and B pathways is mandatory for the development of early viral hepatitis but not for recovery from viral infection. J Virol 75(18):8781–8791PubMedCrossRef
104.
Zheng SJ, Wang P, Tsabary G, Chen YH (2004) Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 113(1):58–64PubMed
105.
Mundt B, Kuhnel F, Zender L, Paul Y, Tillmann H, Trautwein C, Manns MP, Kubicka S (2003) Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 17(1):94–96PubMed
106.
Osman Y, Kawamura T, Naito T, Takeda K, Van Kaer L, Okumura K, Abo T (2000) Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur J Immunol 30(7):1919–1928PubMedCrossRef
107.
Saitou Y, Shiraki K, Fuke H, Inoue T, Miyashita K, Yamanaka Y, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T (2005) Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases. Hum Pathol 36(10):1066–1073PubMedCrossRef
108.
Gilles PN, Guerrette DL, Ulevitch RJ, Schreiber RD, Chisari FV (1992) HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-gamma. Hepatology 16(3):655–663PubMedCrossRef
109.
Dong Z, Wei H, Sun R, Tian Z (2007) The roles of innate immune cells in liver injury and regeneration. Cell Mol Immunol 4(4):241–252PubMed
110.
Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K (2000) Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 97(10):5498–5503PubMedCrossRef
111.
Toyabe S, Seki S, Iiai T, Takeda K, Shirai K, Watanabe H, Hiraide H, Uchiyama M, Abo T (1997) Requirement of IL-4 and liver NK1+ T cells for concanavalin A-induced hepatic injury in mice. J Immunol 159(3):1537–1542PubMed
112.
Kaneko Y, Harada M, Kawano T, Yamashita M, Shibata Y, Gejyo F, Nakayama T, Taniguchi M (2000) Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 191(1):105–114PubMedCrossRef
113.
Kusters S, Gantner F, Kunstle G, Tiegs G (1996) Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 111(2):462–471PubMedCrossRef
114.
Tagawa Y, Kakuta S, Iwakura Y (1998) Involvement of Fas/Fas ligand system-mediated apoptosis in the development of concanavalin A-induced hepatitis. Eur J Immunol 28(12):4105–4113PubMedCrossRef
115.
Kusters S, Tiegs G, Alexopoulou L, Pasparakis M, Douni E, Kunstle G, Bluethmann H, Wendel A, Pfizenmaier K, Kollias G, Grell M (1997) In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 27(11):2870–2875PubMedCrossRef
116.
Trobonjaca Z, Kroger A, Stober D, Leithauser F, Moller P, Hauser H, Schirmbeck R, Reimann J (2002) Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation. J Immunol 168(8):3763–3770PubMed
117.
Nakagawa R, Nagafune I, Tazunoki Y, Ehara H, Tomura H, Iijima R, Motoki K, Kamishohara M, Seki S (2001) Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol 166(11):6578–6584PubMed
118.
Vilarinho S, Ogasawara K, Nishimura S, Lanier LL, Baron JL (2007) Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. Proc Natl Acad Sci USA 104(46):18187–18192PubMedCrossRef
119.
Sun R, Tian Z, Kulkarni S, Gao B (2004) IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners. J Immunol 172(9):5648–5655PubMed
120.
Li B, Sun R, Wei H, Gao B, Tian Z (2006) Interleukin-15 prevents concanavalin A-induced liver injury in mice via NKT cell-dependent mechanism. Hepatology 43(6):1211–1219PubMedCrossRef
121.
Schumann J, Wolf D, Pahl A, Brune K, Papadopoulos T, van Rooijen N, Tiegs G (2000) Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol 157(5):1671–1683PubMedCrossRef
122.
Su GL (2002) Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am J Physiol Gastrointest Liver Physiol 283(2):G256–G265PubMed
123.
Sitia G, Iannacone M, Aiolfi R, Isogawa M, van Rooijen N, Scozzesi C, Bianchi ME, von Andrian UH, Chisari FV, Guidotti LG (2011) Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. PLoS Pathog 7(6):e1002061PubMedCrossRef
124.
Yoneyama H, Ichida T (2005) Recruitment of dendritic cells to pathological niches in inflamed liver. Med Mol Morphol 38(3):136–141PubMedCrossRef
125.
Ojiro K, Ebinuma H, Nakamoto N, Wakabayashi K, Mikami Y, Ono Y, Po-Sung C, Usui S, Umeda R, Takaishi H, Yamagishi Y, Saito H, Kanai T, Hibi T (2010) MyD88-dependent pathway accelerates the liver damage of concanavalin A-induced hepatitis. Biochem Biophys Res Commun 399(4):744–749PubMedCrossRef
126.
Du ZX, Wang HQ, Zhang HY, Gao DX (2007) Involvement of glyceraldehyde-3-phosphate dehydrogenase in tumor necrosis factor-related apoptosis-inducing ligand-mediated death of thyroid cancer cells. Endocrinology 148(9):4352–4361PubMedCrossRef
127.
Galanos C, Freudenberg MA, Reutter W (1979) Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 76(11):5939–5943PubMedCrossRef
128.
Jiang W, Sun R, Wei H, Tian Z (2005) Toll-like receptor 3 ligand attenuates LPS-induced liver injury by down-regulation of toll-like receptor 4 expression on macrophages. Proc Natl Acad Sci USA 102(47):17077–17082PubMedCrossRef
129.
Seki E, Tsutsui H, Nakano H, Tsuji N, Hoshino K, Adachi O, Adachi K, Futatsugi S, Kuida K, Takeuchi O, Okamura H, Fujimoto J, Akira S, Nakanishi K (2001) Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta. J Immunol 166(4):2651–2657PubMed
130.
Jiang W, Sun R, Zhou R, Wei H, Tian Z (2009) TLR-9 activation aggravates concanavalin A-induced hepatitis via promoting accumulation and activation of liver CD4+ NKT cells. J Immunol 182(6):3768–3774PubMedCrossRef
131.
Wang J, Sun R, Wei H, Dong Z, Gao B, Tian Z (2006) Poly I: C prevents T cell-mediated hepatitis via an NK-dependent mechanism. J Hepatol 44(3):446–454PubMedCrossRef
132.
Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ (2010) Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464(7285):104–107PubMedCrossRef
133.
Vodovotz Y, Liu S, McCloskey C, Shapiro R, Green A, Billiar TR (2001) The hepatocyte as a microbial product-responsive cell. J Endotoxin Res 7(5):365–373PubMed
134.
Dalpke AH, Lehner MD, Hartung T, Heeg K (2005) Differential effects of CpG-DNA in Toll-like receptor-2/-4/-9 tolerance and cross-tolerance. Immunology 116(2):203–212PubMedCrossRef
135.
Tiegs G, Hentschel J, Wendel A (1992) A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 90(1):196–203PubMedCrossRef
136.
Lehmann V, Freudenberg MA, Galanos C (1987) Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and d-galactosamine-treated mice. J Exp Med 165(3):657–663PubMedCrossRef
137.
Minagawa M, Deng Q, Liu ZX, Tsukamoto H, Dennert G (2004) Activated natural killer T cells induce liver injury by Fas and tumor necrosis factor-alpha during alcohol consumption. Gastroenterology 126(5):1387–1399PubMedCrossRef
138.
Ochi M, Ohdan H, Mitsuta H, Onoe T, Tokita D, Hara H, Ishiyama K, Zhou W, Tanaka Y, Asahara T (2004) Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology 39(5):1321–1331PubMedCrossRef
139.
Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, Yagita H, Godfrey DI (2002) Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 99(4):1259–1266PubMedCrossRef
140.
Muhlen KA, Schumann J, Wittke F, Stenger S, Van Rooijen N, Van Kaer L, Tiegs G (2004) NK cells, but not NKT cells, are involved in Pseudomonas aeruginosa exotoxin A-induced hepatotoxicity in mice. J Immunol 172(5):3034–3041PubMed
141.
Emoto M, Miyamoto M, Yoshizawa I, Emoto Y, Schaible UE, Kita E, Kaufmann SH (2002) Critical role of NK cells rather than V alpha 14(+)NKT cells in lipopolysaccharide-induced lethal shock in mice. J Immunol 169(3):1426–1432PubMed
142.
Xiong Q, Hase K, Tezuka Y, Namba T, Kadota S (1999) Acteoside inhibits apoptosis in d-galactosamine and lipopolysaccharide-induced liver injury. Life Sci 65(4):421–430PubMedCrossRef
143.
Nowak M, Gaines GC, Rosenberg J, Minter R, Bahjat FR, Rectenwald J, MacKay SL, Edwards CK 3rd, Moldawer LL (2000) LPS-induced liver injury in d-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor. Am J Physiol Regul Integr Comp Physiol 278(5):R1202–R1209PubMed
144.
Uchikura K, Wada T, Hoshino S, Nagakawa Y, Aiko T, Bulkley GB, Klein AS, Sun Z (2004) Lipopolysaccharides induced increases in Fas ligand expression by Kupffer cells via mechanisms dependent on reactive oxygen species. Am J Physiol Gastrointest Liver Physiol 287(3):G620–G626PubMedCrossRef
145.
Shuto Y, Kataoka M, Higuchi Y, Matsuura K, Hijiya N, Yamamoto S (2004) Roles of CD14 in LPS-induced liver injury and lethality in mice pretreated with Propionibacterium acnes. Immunol Lett 94(1–2):47–55PubMedCrossRef
146.
Hishinuma I, Nagakawa J, Hirota K, Miyamoto K, Tsukidate K, Yamanaka T, Katayama K, Yamatsu I (1990) Involvement of tumor necrosis factor-alpha in development of hepatic injury in galactosamine-sensitized mice. Hepatology 12(5):1187–1191PubMedCrossRef
147.
Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, Yoshimatsu H (2004) Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 40(1):177–184PubMedCrossRef
148.
Ambade A, Catalano D, Lim A, Mandrekar P (2011) Inhibition of hsp90 attenuates pro-inflammatory cytokines and prevents LPS induced liver injury. Hepatology 55:1585–1595CrossRef
149.
Kawakami Y, Tomimori Y, Yumoto K, Hasegawa S, Ando T, Tagaya Y, Crotty S, Kawakami T (2009) Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J Exp Med 206(6):1219–1225PubMedCrossRef
150.
Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z, Jaung MS, Blaser BW, Sun J, Benson DM Jr, Mao H, Yokohama A, Bhatt D, Shen L, Davuluri R, Weinstein M, Marcucci G, Caligiuri MA (2006) Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity 24(5):575–590PubMedCrossRef
151.
Yang G, Liu A, Xie Q, Guo TB, Wan B, Zhou B, Zhang JZ (2007) Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Int Immunol 19(2):133–140PubMedCrossRef
152.
Li J, Wu W, Peng G, Chen F, Bai M, Zheng M, Chen Z (2010) HBcAg induces interleukin-10 production, inhibiting HBcAg-specific Th17 responses in chronic hepatitis B patients. Immunol Cell Biol 88(8):834–841PubMedCrossRef
153.
Yao S, Wang S, Zhu Y, Luo L, Zhu G, Flies S, Xu H, Ruff W, Broadwater M, Choi IH, Tamada K, Chen L (2009) PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood 113(23):5811–5818PubMedCrossRef
154.
Cho HY, Choi EK, Lee SW, Jung KO, Seo SK, Choi IW, Park SG, Choi I (2009) Programmed death-1 receptor negatively regulates LPS-mediated IL-12 production and differentiation of murine macrophage RAW264.7 cells. Immunol Lett 127(1):39–47PubMedCrossRef
155.
Golden-Mason L, Klarquist J, Wahed AS, Rosen HR (2008) Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol 180(6):3637–3641PubMed
156.
Chen Y, Wu S, Guo G, Fei L, Guo S, Yang C, Fu X, Wu Y (2011) Programmed death (PD)-1-deficient mice are extremely sensitive to murine hepatitis virus strain-3 (MHV-3) infection. PLoS Pathog 7(7):e1001347PubMedCrossRef
157.
Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z (2008) PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 45(4):963–970PubMedCrossRef
158.
Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, Zhao JM, Zhang B, Shi M, Ding X, Tang Z, Fu YX, Wang FS (2006) Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 177(1):739–747PubMed
159.
Peng G, Li S, Wu W, Sun Z, Chen Y, Chen Z (2008) Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology 123(1):57–65PubMedCrossRef
160.
Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, Janssen HL (2005) Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41(4):771–778PubMedCrossRef
161.
Han Q, Zhang C, Zhang J, Tian Z (2011) Involvement of activation of PKR in HBx-siRNA-mediated innate immune effects on HBV inhibition. PLoS One 6(12):e27931PubMedCrossRef
Metadata
Title
The role of innate immunity in HBV infection
Authors
Qiuju Han
Cai Zhang
Jian Zhang
Zhigang Tian
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 1/2013
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-012-0331-y

Other articles of this Issue 1/2013

Seminars in Immunopathology 1/2013 Go to the issue

Review

Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside

Review

Lipids and HCV

Review

Innate immune responses in hepatitis C virus infection

Review

Occult HBV infection

Review

HCV in liver transplantation

Review

Experimental models and therapeutic approaches for HBV
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits